Back to stocks
AVTX

AVTX

Avalo Therapeutics, Inc.• Healthcare

Q3 2026 filings are still coming in. 13F filers have 45 days after the quarter ends to report, through November 14, 2026. These totals cover only the funds that have filed so far and will keep rising.
Institutional holders
18
Partial Q3 2026
Total 13F value
$3.9M
Filed positions so far
New positions
9
This quarter
Sold positions
0
This quarter

Top holders

Institutions with disclosed positions in this stock

FundValueShares% PortfolioChange

Centerbook Partners Lp

$2.4M153.3K0.11%+15.4%

Moody Aldrich Partners Llc

$1.2M76.5K0.22%-39.1%

Profund Advisors Llc

$347K22.6K0.01%-20.1%

Pfs Partners, Llc

$31K2.0K0.01%Unchanged

Sterling Capital Management Llc

$21K1.3K0.00%+174.1%

State Of Wyoming

$6K3600.00%New Position

Nisa Investment Advisors, Llc

$4K2610.00%New Position

Gamma Investing Llc

$3K1890.00%New Position

Signaturefd, Llc

$1K820.00%New Position

Versant Capital Management, Inc

$782510.00%New Position

Fortitude Family Office, Llc

$460300.00%Unchanged

Parkside Financial Bank & Trust

$460300.00%New Position

Sjs Investment Consulting Inc.

$430280.00%New Position

Assetmark, Inc

$337220.00%Unchanged

Corecap Advisors, Llc

$199130.00%New Position

Farther Finance Advisors, Llc

$184120.00%New Position

Activest Wealth Management

$1510.00%Unchanged

Key Financial Inc

$1510.00%Unchanged

Explore